Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9% by 2032 | DelveInsight – PR Newswire

The dynamics of the complicated urinary tract infection market are anticipated to change in the coming years owing to the improvement in the rise in the number of healthcare spending across the world and rising cases of complicated urinary tract infection. Leading companies like Allecra Therapeutics, Venatorx Pharmaceuticals, Wockhardt, and others are developing drugs for complicated urinary tract infection treatment.

LAS VEGAS, Sept. 12, 2022 /PRNewswire/ --DelveInsight's Complicated Urinary Tract Infections Market Insights report includes a comprehensive understanding of current treatment practices, complicated urinary tract infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Complicated Urinary Tract Infections Market Report

Discover which therapies are expected to grab major complicated urinary tract infections market share @Complicated Urinary Tract Infections Market Report

Complicated Urinary Tract Infections Overview

Urinary tract infections (UTIs) are among the most common bacterial infections. Clinically, they can manifest in various ways, ranging from relatively benign, uncomplicated infections to complicated UTIs (cUTIs), pyelonephritis, and severe urosepsis. cUTI is a multifaceted entity with numerous forms. Infection from microorganisms is among the major complicated urinary tract infections causes.

Complicated urinary tract infection symptoms such as increased urinary frequency, urgency, hematuria, dysuria, suprapubic or flank discomfort are the most important clinical criteria for the initial complicated urinary tract infection diagnosis. Furthermore, there must be a suitable clinical scenario in which the most likely cause of these complicated urinary tract infection symptoms is a urogenital tract infection.

The complicated urinary tract infections treatment goals are to eliminate the infection, avoid complications, and provide symptomatic relief. Early complicated urinary tract infection treatment is recommended to reduce the risk of developing pyelonephritis.

Complicated Urinary Tract Infections Epidemiology Segmentation

As per DelveInsight, there were approximately 8 million complicated urinary tract infections diagnosed incident casesin the 7MM in 2021.

Among the 7MM, the US had recorded the highest diagnosed incidence of complicated urinary tract infectionsin 2021.

The complicated urinary tract infections market reportproffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

Download the report to understand which factors are driving complicated urinary tract infections epidemiology trends @Complicated Urinary Tract Infections Epidemiological Insights

Complicated Urinary Tract Infections Treatment Market

Complicated UTIs are treated with broader antimicrobial coverage and may require intravenous antibiotics depending on severity. For difficult lower UTIs, broad-spectrum antibiotic therapy should be used for 714 days and curable underlying causes should be treated. Recurrent UTIs are common in women, and antibiotic prophylaxis may be recommended. Catheter-associated urinary tract infection (CAUTI) is one of the most common infections associated with healthcare, and it is treated with catheter removal or replacement as well as antibiotic medication. CAUTIs are frequently caused by resistant bacteria. Pregnant women should be tested and treated for UTIs and asymptomatic bacteriuria, respectively.

Moreover, Avycaz was approved in the United States in February 2015 for the treatment of adult patients with complex urinary tract infections (cUTI), including pyelonephritis, caused by identified susceptible bacteria such as certain Enterobacteriaceae and Pseudomonas aeruginosa. It was approved in Europe in June 2016. The company expanded its label for pediatric patients in the US market in March 2019 and in Europe in November 2020. Allergan and Abbvie have US rights to the drug's development, while Pfizer has market rights outside of the US. The only drugs approved for adult and pediatric patient pools are Zerbaxa and Avycaz. Other drugs approved by the FDA and EMA for complicated urinary tract infection treatment include Recarbrio (Merck), Fetroja (Shionogi), Vabomere (Melinta therapeutics), and Zemdri (Cipla therapeutics).

To know more about complicated urinary tract infections treatment options, visit @New Treatment forComplicated Urinary Tract Infections

Complicated Urinary Tract Infections Pipeline Therapies and Key Companies

Learn more about the complicated urinary tract infectionstherapies in clinical trials @Drugs forComplicated Urinary Tract Infections Treatment

Complicated Urinary Tract Infections Market Dynamics

With increasing multidrug resistance and antibiotic overuse, the prevalence of cUTIs is expected to rise in the future, propelling the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for cUTI is expected to aid complicated urinary tract infections market growth.

Moreover, antibiotics are in high demand as they are the only treatment for cUTIs and UTIs. There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market. Furthermore, increased mergers/acquisitions and collaborations between companies to develop safe and effective drugs will accelerate complicated urinary tract infections market growth.

However, inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus impeding the growth of the complicated urinary tract infections market.

Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to impede clinical trial study evaluation in the complicated urinary tract infections market.

As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis, complex regulatory requirements are expected to hinder the growth of the complicated urinary tract infections market.

Furthermore, conflicting guidelines on uncomplicated urinary tract infections issued by various organizations cause confusion among providers that will further impact the growth of the complicated urinary tract infections market.

Scope of the Complicated Urinary Tract InfectionsMarket Report

Discover more about drugs for complicated urinary tract infectionsin development @Complicated Urinary Tract Infections Clinical Trials

Table of Contents

Complicated Urinary Tract Infections Market Key Insights

Complicated Urinary Tract Infections Market Report Introduction

Complicated Urinary Tract Infections Market Overview at a Glance

Complicated Urinary Tract Infections Market Executive Summary

Disease Background and Overview

Complicated Urinary Tract Infections Treatment and Management

Complicated Urinary Tract Infections Epidemiology and Patient Population

Patient Journey

Complicated Urinary Tract Infections Marketed Drugs

10.

Complicated Urinary Tract Infections Emerging Drugs

11.

Seven Major Complicated Urinary Tract Infections Market Analysis

12.

Complicated Urinary Tract Infections Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Complicated Urinary Tract Infections Market Drivers

16.

Complicated Urinary Tract Infections Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Get in touch with our business executive@Healthcare Due Diligence Services

Related Reports

Complicated Urinary Tract Infections Epidemiology Forecast

Complicated Urinary Tract InfectionsEpidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the complicated urinary tract infectionsepidemiology trends.

Complicated Urinary Tract Infections Pipeline

Complicated Urinary Tract InfectionsPipeline Insight 2022report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key complicated urinary tract infections companies, including Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allecra Therapeutics, among others.

Uncomplicated Urinary Tract Infections Pipeline

Uncomplicated Urinary Tract InfectionsPipeline Insight 2022report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key uncomplicated urinary tract infections companies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.

Uncomplicated Urinary Tract Infections Market

Uncomplicated Urinary Tract InfectionsMarket Insights, Epidemiology, and Market Forecast 2032report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key uncomplicated urinary tract infectionscompanies, including Venatorx Pharmaceuticals, Allecra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, among others.

Uncomplicated Urinary Tract Infections Epidemiology

Uncomplicated Urinary Tract InfectionsEpidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the uncomplicated urinary tract infectionsepidemiology trends.

Other Trending Reports

AboutDelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.

Connect with us onLinkedIn|Facebook|Twitter

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

Complicated Urinary Tract Infections Market to Witness Growth at a CAGR of 5.9% by 2032 | DelveInsight - PR Newswire